Diclofenac /ml

Phase 2Small molecule

AAksaray University Training and Research Hospital

Diclofenac /ml is one of 47 small molecule programs targeting Low back pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainEnrolling by invitation

Low Back PainPhase 2

Enrolling by invitation

Competition

Competitive Landscape

56 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

9 2

Aleve

Jazz Pharmaceuticals

Approved

5 3

Voltaren

Novartis

Approved

4 4

Advil

KKenvue Brands

Approved

13 5

Lioresal

Novartis

Approved

1 6

Toradol

Roche

Approved

1 7

Celebrex

PPhiladelphia Eye Associates

Approved

6 8

Oxycontin

PProtega

Approved

5 9

Bayer Aspirin

Bayer

Approved

—10

MS Contin

HHikma Pharmaceuticals LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low back pain1 trial

Comparison of the Efficacy of Diclofenac Sodium and Subcutaneous 5% Dextrose Injection in Low Back Pain.

Enrolling by invitation·—·Phase 1/2·NCT06829030·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Diclofenac /ml. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diclofenac /ml compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diclofenac /ml. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aksaray University Training and Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAksaray University Training and Research Hospital

Diclofenac /ml

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Low back pain1 trial

References

Drug Info

Quick Facts

Related News